EasyM™: Blood-based MRD Monitoring
EasyM is an ultrasensitive clonotypic peptides mass spectrometry blood test for minimal residual disease (MRD) monitoring in multiple myeloma.
EasyM measures the M-spike proteins (myeloma protein or M-protein), a biomarker produced by myeloma cells, to extremely low levels in the peripheral blood.
This allows for convenient, non-invasive and highly sensitive MRD testing for multiple myeloma patients in complete response (CR) as frequently as needed.
serum protein electrophoresis (SPEP); immunofixation electrophoresis (IFE)
How Does EasyM Work?
EasyM is powered by Rapid Novor’s proprietary REmAb® de novo protein sequencing platform. Our world leading expertise in mass spectrometry enables highly accurate and reliable sequencing of the patient’s M-spike.
EasyM does not require bone marrow aspirates, unlike standard MRD tests for multiple myeloma such as next-generation flow cytometry (NGF) or next-generation sequencing (NGS).
The EasyM assay involves two steps:
- Diagnostic Sequencing:
We use tandem mass spectrometry to sequence the patient’s M-spike protein from a baseline serum sample with measurable M-spike. We then identify and validate patient-specific clonotypic peptides for follow-up testing. This is a one time process. - MRD Monitoring:
EasyM quantifies the M-spike by detecting the clonotypic peptide signature in follow-up serum samples, surpassing the detection limits of conventional blood tests.
Test results available within
5-10 working days.
Getting Started.
Clinicians looking to order EasyM for patients or include EasyM in clinical trials should contact us for more information.
We will work with you to provide access to EasyM testing in your area.
EasyM is currently certified for clinical use under CLIA in all US states with the exception of NY.
EasyM has not been cleared by the FDA and is not yet covered by commercial health insurance or Medicare/Medicaid.